Abstract
METCAM/MUC18, an integral membrane cell adhesion molecule (CAM) in the Ig-like gene superfamily, is not expressed in most normal prostate gland, or in all BPH, but overly expressed in most malignant prostate cancer. Its over-expression also correlates with the malignant progression of mouse prostatic adenocarcinoma in a TRAMP model, suggesting that it may be a diagnostic marker for malignant prostate cancer. To demonstrate this, three immunological methods are developed to show promises to use METCAM/MUC18 as a diagnostic marker for the presence of clinical prostate cancer. Enforced expression of METCAM/MUC18 in a human prostate cancer cell line, LNCaP, promotes tumorigenesis and initiates metastasis to multiple organs in a male nude mouse model, suggesting that it can promote the malignant progression of prostate cancer. ShRNAs in a lentivirus vector could decrease the tumorigenesis of another human prostate cancer cell line, DU145, in a male athymic nude mouse model. Taken together, METCAM/MUC18 is a new diagnostic marker of and a driver for promoting the malignant progression of and its specific siRNAs, oligo-peptides, and antibodies may be used for therapeutic treatments of clinical prostate cancer.

This publication has 11 references indexed in Scilit: